Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
(2024) Future Oncology — Vol. 20, n° 18, p. 1237-1250 (2024)
Files
STUDYD1.pdf
Open Access - Adobe PDF
- 2.27 MB
Details
- Authors
- Abstract
- Trastuzumab deruxtecan (T-DXd) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (mBC). Results on T-DXd treatment in HER2-low mBC have so far been limited to clinical trials. DESTINY-Breast Respond HER2-low Europe (NCT05945732) is a multi-center, multi-country, observational, prospective, non-interventional study planning to enroll 1350 patients from 216 sites receiving T-DXd or conventional chemotherapy as their routine clinical care for advanced stage breast cancer in 12 European countries. This non-interventional study will provide real-world insight into T-DXd treatment for HER2-low mBC with data on effectiveness, safety and tolerability, patient-reported outcomes, treatment patterns, geriatric health status and HER2 testing. This will be beneficial for improving guidance to maximize patient treatment benefit.
- Affiliations
Citations
Guarneri, V., Passos Coelho, J. L., Duhoux, F., Egle, D., García-Sáenz, J. Á., Penault-Llorca, F., Selander, K., Wildiers, H., Zaman, K., Laeis, P., Lucerna, M., & Pierga, J.-Y. (2024). Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer. Future Oncology, 20(18), 1237-1250. https://doi.org/10.2217/fon-2024-0015 (Original work published 2024)